The results, presented at the first Annual World Congress on Insulin Resistance Syndrome, held in Los Angeles last month, found that a combination of chromium picolinate and the fatty acid conjugated linoleic acid (CLA), gaining attention for its fat reduction effect, resulted in a significant weight loss in animals. The combination decreased renal fat pad weight with a greater effect than that of each nutrient alone.
The findings strongly suggest that the combination may be involved with the transcription factors in insulin pathway and thereby helps in reducing the risk of diabetes and metabolic syndrome, said the researchers.
Previous studies have demonstrated that chromium picolinate can improve insulin sensitivity and reduce diabetes risk. The New York-based company had also found the novel combination with CLA, branded as Zenergen, to boost glucose uptake and glycogen synthesis in vitro.
According to the American Academy of Clinical Endocrinologists (AACE), a co-sponsor of the congress, Insulin Resistance Syndrome or Metabolic Syndrome is a physiological metabolic problem, characterized by decreased tissue sensitivity to the action of insulin.
Most people with insulin resistance are able to secrete enough insulin to maintain non-diabetic glucose levels, but are at increased risk of developing cardiovascular disease ( the leading cause of death in the United States), diabetes, liver disease and certain types of cancer.